Plasma tissue factor antigen in localized prostate cancer: Distribution, clinical significance and correlation with haemostatic activation markers

Florian Langer; Felix Kyoung-Hwan Chun; Ali Amirkhosravi; Martin Friedrich; Sven Leuenroth; Barbara Eifrig; Carsten Bokemeyer; John L. Francis

doi:10.1160/TH06-09-0523

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 97(03): 464-470
DOI: 10.1160/TH06-09-0523

Cellular Proteolysis and Oncology

Schattauer GmbH

Plasma tissue factor antigen in localized prostate cancer: Distribution, clinical significance and correlation with haemostatic activation markers

Authors

Florian Langer

¹II. Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Hamburg, Germany
Felix Kyoung-Hwan Chun

²Klinik und Poliklinik für Urologie, Universitätsklinikum Eppendorf, Hamburg, Germany
Ali Amirkhosravi

³Florida Hospital Institute of Translational Research, Orlando, Florida, USA
Martin Friedrich

²Klinik und Poliklinik für Urologie, Universitätsklinikum Eppendorf, Hamburg, Germany
Sven Leuenroth

⁴Institut für Pathologie, Universitätsklinikum Eppendorf, Hamburg, Germany
Barbara Eifrig

¹II. Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Hamburg, Germany
Carsten Bokemeyer

¹II. Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Hamburg, Germany
John L. Francis

³Florida Hospital Institute of Translational Research, Orlando, Florida, USA

Abstract

Summary

Tissue factor (TF) is involved in cancer growth and metastasis, and haemostatic abnormalities are found in most patients with advanced malignancies, including prostate cancer (PC). Because anti-haemostatic agents are increasingly screened for their potential to prolong survival in tumor patients, a detailed characterization of haemostatic markers in selected cancer subtypes and clinical stages is warranted. In this study, we measured preoperative plasma TF antigen in a large cohort of patients with localized PC and correlated its levels with markers of coagulation and platelet activation, prostate-specific antigen (PSA), and his-topathological findings to explore its potential as a prognostic marker in this tumor entity. Out of 140 patients, 19% and 23% had plasma TF antigen levels of <40 pg/ml (low-TF) and >200 pg/ ml (high-TF), respectively, which was substantially higher than in 42 healthy male controls. Patients also had low-grade systemic coagulation activation as evidenced by elevated D-dimer, FI +2, and PAP plasma levels. Furthermore, similar to sP-selectin and sCD40L antigen, flow cytometric analysis of platelet-derived microparticles in plasma revealed significantly increased numbers in high-TF as compared to low-TF patients and controls. Whereas elevated D-dimer was associated with larger and less differentiated tumors, preoperative plasmaTF antigen levels (median [IQR]) were higher in patients with (161 pg/ml [100-236]) than in those without recurrent PC (105 pg/ml [52-182]), as indicated by a serum PSA of >0.1 ng/ml during ambulatory follow-up. In patients with localized PC, preoperative plasma TF antigen levels correlate with platelet activation in vivo and may indicate an increased risk for recurrent disease.

Keywords

Tissue factor/factor VII - cancer - microparticles

Full Text

References

References
1 Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015-1022.
2 Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005; 25: 1545-1550.
3 Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006; 32: 61-68.
4 Kakkar AK, Lemoine NR, Scully MF. et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82: 1101-1104.
5 Shigemori C, Wada H, Matsumoto K. et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998; 80: 894-898.
6 Koomagi R, Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998; 79: 19-22.
7 Abdulkadir SA, Carvalhal GF, Kaleem Z. et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000; 31: 443-447.
8 Ohta S, Wada H, Nakazaki T. et al. Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res 2002; 22: 2991-2996.
9 Seitz R, Rappe N, Kraus M. et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis 1993; 4: 249-254.
10 Oya M, Akiyama Y, Okuyama T. et al. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 2001; 31: 388-394.
11 Dirix LY, Salgado R, Weytjens R. et al. Plasma fibrin D-dimer levels correlate with tumor volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-395.
12 Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003; 97: 3044-3052.
13 Lind SE, Caprini JA, Goldshteyn S. et al. Correlates of thrombin generation in patients with advanced prostate cancer. Thromb Haemost 2003; 89: 185-189.
14 Bogdanov VY, Balasubramanian V, Hathcock J. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9: 458-462.
15 Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006; 32: 11-23.
16 Parhami-Seren B, Butenas S, Krudysz-Amblo J. et al. Immunologic quantitation of tissue factor. J Thromb Haemost 2006; 4: 1747-1755.
17 Lim HS, Blann AD, Lip GYH. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus. Circulation 2004; 109: 2524-2528.
18 Sase T, Wada H, Kamikura Y. et al. Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases. Thromb Haemost 2004; 92: 132-139.
19 Mohan JS, Lip GYH, Wright J. et al. Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and to inflammation. Blood Coagul Fibrinolysis 2005; 16: 209-214.
20 Kim HK, Song KS, Park YS. et al. Changes of plasma tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease. Cardiology 2000; 93: 31-36.
21 Han LY, Landen Jr CN, Kamat AA. et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 2006; 24: 755-761.
22 Kohli M, Fink LM, Spencer HJ. et al. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis 2002; 13: 1-5.
23 Kohli M, Kaushal V, Mehta P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Haemost 2003; 29: 301-308.
24 de la Fouchardière C, Flechon A, Droz JP. Coagulopathy in prostate cancer. Neth J Med 2003; 61: 347-354.
25 Bill-Axelson A, Holmberg L, Ruutu M. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-1984.
26 Kakkar AK, Levine MN, Kadziola Z. et al. Low molecular weight heparin, therapy with Dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948.
27 Lee AY, Rickles FR, Julian JA. et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-2129.
28 Combes V, Dignat-George F, Mutin M. et al. A new flow cytometry method of platelet-derived microvesicle quantitation in plasma. Thromb Haemost 1997; 77: 220
29 Roselli M, Mineo TC, Basili S. et al. Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res 2004; 10: 610-614.
30 Caine JC, Lip GYH, Stonelake PSS. et al. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004; 92: 185-190.
31 Butenas S, Bouchard BA, Brummel-Ziedins KE. et al. Tissue factor activity in whole blood. Blood 2005; 105: 2764-2770.
32 Fink L, Holschermann H, Kwapiszewska G. et al. Characterization of platelet-specific mRNA by realtime PCR after laser-assisted microdissection. Thromb Haemost. 2003: 749-756.
33 Camera M, Frigerio M, Toschi V. et al. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler Thromb Vasc Biol 2003; 23: 1690-1696.
34 Siddiqui FA, Desai H, Amirkhosravi A. et al. The presence and release of tissue factor from human platelets. Platelets 2002; 13: 247-253.
35 Muller I, Klocke A, Alex M. et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003; 17: 476-478.
36 Osterud B. The role of platelets in decrypting monocyte tissue factor. Semin Hematol 2001; 38: 2-5.
37 Del Conde I, Shrimpton CN, Thiagarajan P. et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-1611.
38 Nakashima J, Tachibana M, Ueno M. et al. Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res 1995; 55: 4881-4885.
39 Schwertz H, Tolley ND, Foulks JM. et al. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenecity of human platelets. J Exp Med 2006; 203: 2433-2440.
40 Akashi T, Furuya Y, Ohta S. et al. Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology 2003; 62: 1078-1082.